Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | LMNA | P02545 | 5/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | TOP2A | P11388 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL9788110 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2465661 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL23064249 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL1281819 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL27004 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2325952 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2636760 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL184706 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL8530004 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL4459712 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7885 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079427-A | Method for degrading organic pollutants by coupling nano-confinement catalytic membrane with micro-nano bubbles | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026090462-A1 | STABLE CIPROFLOXACIN COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120115168-A | Aluminum-based nano-oxidase and preparation method and application thereof | 广东工业大学 | 2025-06-10 | — | — | CN | claimed |
| CN-120078752-A | Particles for large-dose water-soluble medicine inhalation powder aerosol and preparation method thereof | 沈阳药科大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120058851-A | Ciprofloxacin nano prodrug, preparation method and application thereof | 天津工业大学 | 2025-05-30 | — | — | CN | claimed |
| EP-4555375-A1 | METHODS OF MAKING AND USING CONTACT LENSES INCLUDING MEDICAMENTS AND STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS | Doshi, Praful (US) | 2025-05-21 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| EP-0696201-A4 | SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE | AMERICAN NAT RED CROSS (US) | 1996-06-26 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0696201-A1 | SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE | AMERICAN NATIONAL RED CROSS (US) | 1996-02-14 | — | — | EP | claimed |
| CN-1115641-A | Prepn of cyclopropyloxacini injecta | NORTHEAST GENERAL PHARMACEUTIC (CN) | 1996-01-31 | — | — | CN | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1994020133-A1 | SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE | THE AMERICAN NATIONAL RED CROSS (US) | 1994-09-15 | — | — | WO | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0394553-A2 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | claimed |